AWM
YMAB

Avior Wealth Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Avior Wealth Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8
Closed -$130 – 3767
2024
Q1 		$130 Buy
+8
New +$108 ﹤0.01% 3073

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Avior Wealth Management's YMAB Position: Q2 2024 in Review

Avior Wealth Management sold out of Y-mAbs Therapeutics (YMAB) in Q2 2024, closing a stake of 8 shares — an estimated $130 sold.

Avior Wealth Management first reported a position in YMAB in Q1 2024 and held it in 1 quarter. The position peaked at $130 in Q1 2024. 96 funds tracked by Wall St. Rank hold YMAB as of Q2 2024.

  • Avior Wealth Management reported no remaining Y-mAbs Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 8 Y-mAbs Therapeutics shares in Q2 2024, an estimated $130.
  • Avior Wealth Management first reported a position in Y-mAbs Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Y-mAbs Therapeutics position peaked at $130 in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.